Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

GR-20263

Known as: GR 20263, GR20263 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
SummaryMinimal inhibitory concentrations (MIC) and minimal bactericidal concentrations (MBC) were determined for ceftazidime (GR… Expand
  • table 1
  • table 2
1982
1982
The in vitro activities of moxalactam, GR 20263, and N-formimidoyl thienamycin were compared to those of cephalothin, cefazolin… Expand
1981
1981
The anti-pseudomonal activity of ceftazidime was determined by an agar-dilution technique against 92 strains of Pseudomonas… Expand
1981
1981
Ceftazidime was considerably more active than cefuroxime against 180 strains of resistant species of nosocomial gram-negative… Expand
  • table 1
  • table 2
  • table 3
1981
1981
Ceftazidime was evaluated as an antipseudomonal drug, in a non-comparative study including 10 men and 4 women, at a daily dose of… Expand
1981
1981
Ceftazidime was found to be highly active against routine hospital isolates of strains of Enterobacteriaceae such as Escherichia… Expand
1981
1981
The in-vitro activity of ceftazidime was determined against 586 clinical isolates of anaerobic bacteria by an agar-dilution… Expand
Highly Cited
1980
Highly Cited
1980
GR 20263 is a new broad-spectrum injectable cephalosporin which is stable to most beta-lactamases. Its in vitro activities were… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Highly Cited
1980
Highly Cited
1980
The in vitro activity of GR-20263, a new aminothiazolyl cephalosporin, was compared with the activities of other beta-lactam… Expand
  • table 1
  • table 2
  • table 3
  • table 4
Highly Cited
1980
Highly Cited
1980
The in vitro activity of GR 20263, a new cephalosporin, was compared primarily with the activities of moxalactam (LY 127935… Expand
  • table 2